Safety Profile: What Clinical Trials Actually Documented Across six clinical trials involving approximately 900 participants, AOD-9604 produced no treatment-related serious adverse events, no immunogenic response, no IGF-1 elevation, and no adverse cardiovascular or metabolic signals
There isn't a universally agreed-upon answer, and frankly, the optimal protocol likely depends on the specific nature of the injury and the goals of the study
Sign up for our newsletter Get weekly updates on all things IV therapy By clicking Sign Up you're confirming that you agree with our Terms and Conditions.
Lethal dose perspective For context, research indicates the lethal dose of GHK-CU in rodent models extrapolates to approximately 21,000mg for a 70kg human, roughly 330mg per kilogram of body weight
For instance, according to Statista, the pharmaceuticals market in the U.S